ALK indicates anaplastic lymphoma kinase; AML, acute myeloid leukemia; BLA, biologic license application; CCR4, CC chemokine receptor type 4; CFTR, cystic fibrosis transmembrane conductance regulator; EGFR, epideral growth factor receptor; FDA, US Food and Drug Administration; FLT3, FMS-like tyrosine kinase; HER2, human epidermal growth factor receptor 2; IDH1, isocitrate dehydrogenase-1; NETs, neuroendocrine tumors; NME, new molecular entity; NSCLC, non–small-cell lung cancer; PARP, poly (ADP-ribose) polymerase; PD, programmed cell death; PI3K, phosphatidylinositol 3-kinase; REMS, Risk Evaluation and Mitigation Strategies.
Return to Top
AML indicates acute myeloid leukemia; FDA, US Food and Drug Administration; G-CSF, granulocyte colony-stimulating factor; NHL, non-Hodgkin lymphoma.
To sign up for our newsletter or print publications, please enter your contact information below.